Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Annual EBITDA margin expands by 170 basis points
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Akums invested Rs. 272 crore in capital expenditure during FY25
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
For over 13 years, Star Imaging has pioneered the introduction of next-generation radiology technologies in Pune
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
Subscribe To Our Newsletter & Stay Updated